Nuvectis Pharma (NVCT) Stock Forecast: StockMap's 2-Week Call
NVCT stock forecast: StockMap's model leans Underperform on Nuvectis Pharma for the two weeks after the Nov 19 close, toward NVCT trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 1 of 3 two-week windows on NVCT since Sep 29; by chance, a call on the same dates was right 47% of the time.
Nuvectis Pharma last closed at $19.84, -2.22% on the session.
Against the IVW growth benchmark the position is +0.11% over the forecast window.
Nuvectis Pharma's market cap is $682.26M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -27 (too close to call).
Where NVCT sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
21 daily calls for NVCT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Nuvectis Pharma in the 9th percentile on return on equity, where 100 is best.
Nuvectis Pharma is classified under Health Care / Biotechnology.
StockMap tracks Nuvectis Pharma as the 148th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Nuvectis Pharma ranks 213th of 394 in the group, against a group median of -0.27.